ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1
Photo by Önder Örtel on Unsplash
Join us at the Asia Dengue Summit 2024!
Connect with Florence Herschke, PhD, our head of preclinical development, and Tessa Van Royen, one of our research scientists, next week at the 7th Asia Dengue Summit in Kuala Lumpur.
Poster ESCMID Global 2024 Conference
Poster presented by CSO Viki Bockstal at ESCMID Global, 27–30 April 2024 in Barcelona, Spain
Member spotlight: ExeVir uses llama-derived antibodies to protect the vulnerable
MEDVIA article featuring ExeVir – Based on the interview with CSO, Viki Bockstal.
By Amy LeBlanc.
Images: Winter the llama ©Tim Coppens
Exevir at ECCMID 2024
Our Chief Scientific Officer Viki Bockstal is presenting a poster at ECSMID Global 2024 (formerly known as ECCMID) from 27-30 April in vibrant Barcelona, the Mediterranean’s #lifesciences hub!
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
Bio-Europe – November 6-8, 2023 – Munich, Germany
Our CEO Torsten Mummenbrauer is attending #BIOEurope in Munich, November 6-8!
ExeVir Bio Appoints a Chief Scientific Officer
Ghent, Belgium, 1 September 2023: ExeVir Bio, a biotech company developing robust single-domain antibody therapies for broad protection against infectious diseases, today announced Dr. Viki Bockstal as its Chief Scientific Officer (CSO) and Caroline Sagaert as its Head of Operations. Jean-Philippe Bultot will become the Company’s Head of Finance and lead ExeVir’s finance and accounting. […]
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
Dengue is a mosquito borne viral infection listed by WHO as top 10 threat for global health
The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO)
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike
Currently circulating SARS-CoV-2 variants have gained complete or significant resistance to all SARSCoV-2-neutralizing antibodies that have been used in the clinic. Such antibodies can prevent severe disease in SARS-CoV-2 exposed patients for whom vaccines may not provide optimal protection. Here, we describe single-domain antibodies (VHHs), also known as nanobodies, that can broadly neutralize SARS-CoV-2 with unusually high potency. Structural analysis revealed their binding to a unique, highly conserved, membrane proximal, quaternary epitope in the S2 subunit of the spike. Furthermore, a VHH-human IgG1 Fc fusion, efficiently expressed in Chinese hamster ovary cells as a stable antibody construct, protected hamsters against SARS-CoV-2 replication in a therapeutic setting when administered systemically at low dose. This VHH-based antibody represents a new candidate anti-COVID-19 biologic that targets the Achilles heel of the viral spike.